-
23andMe’s GHR reports get first direct-to-consumer FDA authorization
SILVER SPRING, Md. — The Food and Drug Administration on Thursday allowed 23andMe to market its Personal Genome Service Genetic Health Risk tests for 10 diseases or conditions directly to consumers. The allowance makes 23andMe’s GHR the first direct-to-consumer test authorized that provides information about a patient’s genetic predisposition to diseases or medical conditions.